Basic Information
| LncRNA/CircRNA Name | FTH1P3 |
| Synonyms | FTH1P3, FTHL3, FTHL3P |
| Region | GRCh38_2:27392784-27393367 |
| Ensemble | ENSG00000213453 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Paclitaxel | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown |
| Sample | breast cancer tissues, cell lines (MCF-7, MDA-MB-231, MDA-MB-468, MDA-MB-453) |
| Expression Pattern | up-regulated |
| Function Description | Results showed that lncRNA FTH1P3 was up-regulated in paclitaxel-resistant breast cancer tissue and cells (MCF-7/PTX and MDA-MB-231/PTX cells) compared with paclitaxel-sensitive tissue and parental cell lines (MCF-7, MDA-MB-231). Gain- and loss-of-function experiments revealed that FTH1P3 silencing decreased the 50% inhibitory concentration (IC50) value of paclitaxel and induced cell cycle arrest at G2/M phase, while FTH1P3-enhanced expression exerted the opposite effects. Bioinformatics tools and luciferase reporter assay validated that FTH1P3 promoted ABCB1 protein expression through targeting miR-206, acting as a miRNA "sponge." |
| Pubmed ID | 29971911 |
| Year | 2018 |
| Title | Long Non-Coding RNA FTH1P3 Activates Paclitaxel Resistance in Breast Cancer Through miR-206/ABCB1 |
External Links
| Links for FTH1P3 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |